6DW Stock Chart & Stats
€0.47
-€0.01(-1.06%)
At close: 4:00 PM EST
€0.47
-€0.01(-1.06%)
Day’s Range― - ―
52-Week Range€0.32 - €0.86
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€24.21M
Enterprise Value€2.55B
Total Cash (Recent Filing)€1.54B
Total Debt (Recent Filing)€594.17M
Price to Earnings (P/E)―
Beta-0.38
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.89
Shares Outstanding57,483,414
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.21
Price to Sales (P/S)11.87
P/FCF Ratio-9.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins near 78% indicate a structurally high-margin product base or cost advantage. This provides a durable cushion against top-line volatility, supports reinvestment in R&D and commercialization, and improves the odds of scalable profitability if revenue grows.
Improving LeverageA materially lower debt-to-equity ratio reduces refinancing and solvency risk, increasing financial flexibility for multi-quarter development cycles typical in biotech. Improved leverage and a larger equity base enhance the firm's ability to fund operations without urgent debt pushes.
Narrowing Losses And BurnProgress toward smaller losses and reduced cash burn shows operational traction or cost control progress. If sustained over multiple quarters, this trend lengthens runway, lowers near-term financing needs, and makes the path to break-even more credible.
Bears Say
Persistent Negative Cash FlowChronic negative operating and free cash flow is a structural weakness that prevents self-funding of operations and R&D. Continued cash burn forces repeated external financing, raising dilution risk and limiting the company’s ability to invest selectively for long-term commercial scaling.
Small, Volatile, Declining RevenueA small and shrinking top line constrains economies of scale and magnifies fixed-cost impact. With revenue falling, it becomes harder to convert high gross margins into operating profit, and the company remains dependent on external capital rather than organic growth to fund expansion.
Net Losses Exceed RevenueLosses larger than revenue signal the business is far from break-even and erode capital cushions. Persistently negative net margins weaken returns on equity and require either accelerated revenue growth, significant cost cuts, or fresh capital, each posing execution or dilution risk over months.
D.Western Therapeutics Institute News
6DW FAQ
What was D.Western Therapeutics Institute, Inc.’s price range in the past 12 months?
D.Western Therapeutics Institute, Inc. lowest stock price was €0.32 and its highest was €0.85 in the past 12 months.
What is D.Western Therapeutics Institute, Inc.’s market cap?
D.Western Therapeutics Institute, Inc.’s market cap is €24.21M.
When is D.Western Therapeutics Institute, Inc.’s upcoming earnings report date?
D.Western Therapeutics Institute, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 8 days.
How were D.Western Therapeutics Institute, Inc.’s earnings last quarter?
D.Western Therapeutics Institute, Inc. released its earnings results on May 14, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.017.
Is D.Western Therapeutics Institute, Inc. overvalued?
According to Wall Street analysts D.Western Therapeutics Institute, Inc.’s price is currently Overvalued.
Does D.Western Therapeutics Institute, Inc. pay dividends?
D.Western Therapeutics Institute, Inc. does not currently pay dividends.
What is D.Western Therapeutics Institute, Inc.’s EPS estimate?
D.Western Therapeutics Institute, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does D.Western Therapeutics Institute, Inc. have?
D.Western Therapeutics Institute, Inc. has 57,483,414 shares outstanding.
What happened to D.Western Therapeutics Institute, Inc.’s price movement after its last earnings report?
D.Western Therapeutics Institute, Inc. reported an EPS of -€0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.395%.
Which hedge fund is a major shareholder of D.Western Therapeutics Institute, Inc.?
Currently, no hedge funds are holding shares in DE:6DW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
D.Western Therapeutics Institute, Inc.
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.